AEE heads into its November earnings with a notably one-sided story in the analyst community: nearly every recent move has been a target cut, even from banks that still like the stock.
The wave of downgrades began mid-August and has not let up. Morgan Stanley cut its target twice in six weeks, from $118 to $114 in late August and then again to $108 on September 18, holding Equal-Weight both times. RBC Capital followed on September 25, trimming from $114 to $107 at Sector Perform. The most pointed move came this week: Mizuho's Anthony Crowdell, who raised his target to $124 as recently as August 3 after strong Q2 numbers, reversed course and cut to $113 on September 30, still Outperform but clearly less convicted. Scotiabank initiated at Sector Perform with a $104 target on September 29, well below the pack. The mean target across the Street is $118.80, implying roughly 18% upside to Tuesday's close of $100.25. Whether that gap reflects genuine opportunity or collective anchor-dragging by analysts slow to reset is the central debate right now.
The bull case leans on Ameren's operational strength. Retail sales rose 3% across all customer classes at Ameren Missouri in the most recent quarter, with a $0.05 year-over-year earnings improvement. The dividend factor score ranks in the 97th percentile, reflecting the stock's income credentials. Valuation has drifted lower over the month: the PE ratio has fallen by more than a full turn in 30 days to 17.6x, and EV/EBITDA has ticked down to 10.9x, making the stock modestly cheaper than it was a month ago. The bears point to timing risk on rate relief: the projected earnings boost from the Missouri electric rate case was expected to arrive in stages through 2025, and share dilution from roughly 5.8 million shares under forward sale agreements adds another headwind to per-share metrics. The analyst recommendation differential ranks in the 91st percentile against peers, a sign that consensus is more positive on AEE than on most utilities, but the relentless target reductions suggest that positivity is being tested.
Short positioning tells a quieter story than the analyst noise might suggest. Short interest has fallen 6% over the week to 4.5% of free float, and is down 13% over the past month. The borrow market is exceptionally loose: availability runs at roughly 1,393%, meaning lenders are sitting on more than thirteen times the volume already borrowed, and cost to borrow has stayed near 0.49%, effectively zero friction for a would-be short seller. The ORTEX short score of 46.7 ranks in the 25th percentile, consistent with a stock that shorts are quietly unwinding rather than pressing. Options positioning has picked up modestly: the put/call ratio rose to 0.53 on September 29, about 1.1 standard deviations above its 20-day average of 0.42, and meaningfully higher than the 0.16 reading seen just the day before. That single-session jump deserves a footnote, the prior day's PCR was anomalously low, so the reversion explains some of the move. Still, the ratio is approaching the upper end of its recent range, suggesting some investors are buying downside insurance ahead of the Q3 print.
One real-economy signal worth noting: ORTEX Alt Data shows that Ameren recorded its smallest June gross capacity factor on record (since 2024), at 29.53%, based on EPA Clean Air Markets Program Data. Separately, the nuclear reactor output signal from the NRC is running 4.8 standard deviations below the reactor's own trailing history as of September 29, the most extreme negative deviation in the dataset. This is an outage-detection signal rather than a revenue forecast, and the nuclear output dataset does not yet have enough history to test whether it leads Ameren's reported figures. It is operational colour, not a predictor of the November print.
Institutional ownership is stable and concentrated. T. Rowe Price holds 11.8% as the largest shareholder, having added 3.9 million shares in its most recent reported period. BlackRock added 2 million shares to reach 9.3%. No 13D activist is on the register; all large holders filed passive 13G disclosures, and stakes are as-last-disclosed, with the caveat that holders can fall below 5% without a further filing.
Insider activity over the past 90 days has been net negative: open-market sales totalling roughly $877,000 on a net basis, led by the SVP Finance and a Group President, though the Group President's $708,000 sale in August was executed under a pre-arranged 10b5-1 plan and carries less signal weight than a discretionary sale. No open-market purchases appear in the window.
With the next earnings print confirmed for November 5, the period ahead is largely about whether the rate case timeline at Ameren Missouri delivers the earnings step-up the Street has been modelling, and whether analysts stabilise their targets or continue trimming.
See the live data behind this article on ORTEX.
Open AEE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
